Acrivon Therapeutics, Inc.
ACRV
$1.52
-$0.06-3.80%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -4.30% | 2.53% | 5.25% | 11.58% | 19.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.70% | 4.28% | 23.74% | 32.42% | 32.93% |
| Operating Income | 5.70% | -4.28% | -23.74% | -32.42% | -32.93% |
| Income Before Tax | 3.29% | -6.20% | -24.57% | -30.62% | -33.40% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 3.29% | -6.20% | -24.57% | -30.62% | -33.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.29% | -6.20% | -24.57% | -30.62% | -33.40% |
| EBIT | 5.70% | -4.28% | -23.74% | -32.42% | -32.93% |
| EBITDA | 6.16% | -3.80% | -23.35% | -32.06% | -32.49% |
| EPS Basic | 16.94% | 21.16% | 18.86% | 22.94% | 10.84% |
| Normalized Basic EPS | 19.74% | 18.43% | 16.21% | 20.35% | 8.25% |
| EPS Diluted | 16.94% | 21.16% | 18.86% | 22.94% | 10.84% |
| Normalized Diluted EPS | 19.74% | 18.43% | 16.21% | 20.35% | 8.25% |
| Average Basic Shares Outstanding | 14.04% | 28.91% | 48.50% | 69.51% | 52.95% |
| Average Diluted Shares Outstanding | 14.04% | 28.91% | 48.50% | 69.51% | 52.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |